$55.63 Million in Sales Expected for Cardiovascular Systems, Inc. (CSII) This Quarter

Wall Street analysts expect that Cardiovascular Systems, Inc. (NASDAQ:CSII) will announce sales of $55.63 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Cardiovascular Systems’ earnings, with the lowest sales estimate coming in at $55.30 million and the highest estimate coming in at $55.90 million. Cardiovascular Systems reported sales of $52.14 million in the same quarter last year, which would suggest a positive year over year growth rate of 6.7%. The company is expected to announce its next quarterly earnings results on Wednesday, May 2nd.

According to Zacks, analysts expect that Cardiovascular Systems will report full-year sales of $55.63 million for the current financial year, with estimates ranging from $215.40 million to $217.20 million. For the next year, analysts anticipate that the business will report sales of $242.45 million per share, with estimates ranging from $235.24 million to $251.24 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Cardiovascular Systems.

How to Become a New Pot Stock Millionaire

Cardiovascular Systems (NASDAQ:CSII) last released its earnings results on Wednesday, February 7th. The medical device company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. The firm had revenue of $52.63 million for the quarter, compared to the consensus estimate of $53.39 million. Cardiovascular Systems had a negative return on equity of 0.50% and a negative net margin of 1.62%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.

CSII has been the topic of several analyst reports. BidaskClub raised Cardiovascular Systems from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Needham & Company LLC downgraded Cardiovascular Systems from a “buy” rating to a “hold” rating and cut their target price for the company from $33.11 to $23.00 in a research report on Friday, December 15th. William Blair reissued a “market perform” rating on shares of Cardiovascular Systems in a research report on Thursday, December 21st. Leerink Swann cut their target price on Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Thursday, February 8th. Finally, Zacks Investment Research raised Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Friday, February 9th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. Cardiovascular Systems presently has an average rating of “Hold” and an average target price of $27.00.

NASDAQ CSII opened at $22.87 on Friday. The company has a market cap of $756.38, a PE ratio of 762.33 and a beta of 2.15. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.13 and a current ratio of 4.65. Cardiovascular Systems has a fifty-two week low of $20.58 and a fifty-two week high of $33.11.

A number of institutional investors have recently made changes to their positions in the business. HBK Investments L P grew its position in Cardiovascular Systems by 3.4% in the 4th quarter. HBK Investments L P now owns 93,600 shares of the medical device company’s stock valued at $2,217,000 after acquiring an additional 3,043 shares during the last quarter. Wells Fargo & Company MN grew its position in Cardiovascular Systems by 8.4% in the 3rd quarter. Wells Fargo & Company MN now owns 47,253 shares of the medical device company’s stock valued at $1,330,000 after acquiring an additional 3,648 shares during the last quarter. US Bancorp DE grew its position in Cardiovascular Systems by 51.7% in the 4th quarter. US Bancorp DE now owns 13,208 shares of the medical device company’s stock valued at $313,000 after acquiring an additional 4,500 shares during the last quarter. Bank of Montreal Can grew its position in Cardiovascular Systems by 12.5% in the 4th quarter. Bank of Montreal Can now owns 53,889 shares of the medical device company’s stock valued at $1,277,000 after acquiring an additional 5,998 shares during the last quarter. Finally, Gamco Investors INC. ET AL grew its position in Cardiovascular Systems by 8.7% in the 4th quarter. Gamco Investors INC. ET AL now owns 88,475 shares of the medical device company’s stock valued at $2,096,000 after acquiring an additional 7,045 shares during the last quarter. 82.55% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3336897/55-63-million-in-sales-expected-for-cardiovascular-systems-inc-csii-this-quarter.html.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Get a free copy of the Zacks research report on Cardiovascular Systems (CSII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Tupperware Brands  Releases FY18 Earnings Guidance
Tupperware Brands Releases FY18 Earnings Guidance
Boston Scientific  Announces  Earnings Results
Boston Scientific Announces Earnings Results
Alliance Data  Raised to Hold at Zacks Investment Research
Alliance Data Raised to Hold at Zacks Investment Research
Cirrus Logic  Downgraded by Zacks Investment Research
Cirrus Logic Downgraded by Zacks Investment Research
Summer Infant  Upgraded to Hold by Zacks Investment Research
Summer Infant Upgraded to Hold by Zacks Investment Research
QNB  Issues  Earnings Results
QNB Issues Earnings Results


© 2006-2018 Ticker Report. Google+.